Molecular Diagnostics Market

Molecular Diagnostics Market by Product & Service (Reagents, Kits), Test Type (Lab, PoC), Sample Type (Blood, Urine), Technology (PCR, INAAT), Application (Infectious, Oncology), End User (Diagnostic Labs, Hospitals), Region - Global Forecast to 2028

Report Code: MD 2521 Jun, 2023, by marketsandmarkets.com

The global molecular diagnostics market in terms of revenue was estimated to be worth $15.6 billion in 2023 and is poised to reach $26.8 billion by 2028, growing at a CAGR of 11.4% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market.

Market growth is largely driven by the increasing prevalence of infectious diseases and cancer and the growing funding for R&D in molecular diagnostics. On the other hand, the unfavorable reimbursement scenario and the high cost of instruments may restrain the growth of this market to a certain extent.

Attractive Opportunities in the Molecular Diagnostics Market

Molecular Diagnostics Market

To know about the assumptions considered for the study, Request for Free Sample Report

Molecular Diagnostics Market

Molecular Diagnostics Market Dynamics

DRIVER: Rising technological advancements in molecular diagnostics in recent years

In recent years, several new technologies have been introduced in the market. Shotgun metagenomic next-generation sequencing is a comprehensive genomics-based test that identifies every known microorganism present in a patient’s sample. Each sample is screened for about 40,000 microorganisms—including bacteria, viruses, parasites, and fungi. The MSI Analysis System detects microsatellite instability (MSI), a form of genomic instability linked to a dominant hereditary cancer called Lynch Syndrome. Sample preparation methods have improved in the field of molecular diagnostics. NANOPEC can help decrease the probability of receiving the wrong diagnosis because the fluorescent signal is too weak or the biomarker concentration is too low. Such technological advancements by various key players will increase the adoption of molecular diagnostics, thus driving market growth in the coming years.

OPPORTUNITY: Growing significance of companion diagnostics in drug development process

Companion diagnostics include tests or assays intended to assist healthcare providers in making treatment decisions for patients based on the best response to therapy. The co-development of companion diagnostics with therapeutic products can significantly alter the drug development process and commercialize drug candidates by yielding safer drugs with enhanced therapeutic efficacy quickly and cost-effectively. With an increase in the demand for high-priced specialist therapies and safer drugs, the market for companion diagnostics is expected to grow at a robust rate. This growing importance of companion diagnostics also provides growth opportunities for the market. The growing availability of such advanced and efficient companion diagnostic tests is expected to support the growth of the market in the coming years.

RESTRAINT: Unfavorable reimbursement scenario for diagnostic companies

Inadequate reimbursements are a major factor restraining the growth of the market. A major challenge faced by most diagnostic companies face in commercializing their tests is getting Medicare and private health insurers to pay for them. In the US, Medicare revised its reimbursement mechanism for some IVD tests, including molecular tests, in 2021. Some of these molecular pathology tests do not have their own Healthcare Common Procedure Coding System (HCPCS) codes and are instead billed using unlisted codes. In such cases, Medicare Administrative Contractors (MACs) establish a payment amount for their local jurisdictions. Medicare does not currently provide genetic testing coverage for individuals without a personal history of cancer (Source: American Society of Clinical Oncology). These factors are expected to affect the US molecular testing market adversely.

CHALLENGE: Operational barriers and shortage of skills across major markets

Clinical laboratories across major markets are still evolving; technicians face operational challenges in ensuring effective sample procurement, storage, and transportation, especially while adopting novel technologies such as NGS and lab-on-a-chip PCR devices. Laboratory spaces also need to be reconfigured to conduct specific molecular diagnostic tests used for pathogen detection to avoid cross-contamination and ensure efficient time management. This results in considerable cost escalations in maintaining and operating advanced molecular diagnostic instruments, particularly those capable of handling a single sample type.

Furthermore, due to the rapid mutation of microbes and the increasing outbreak of epidemics, clinical laboratories need to adopt innovative technologies capable of rapid sample diagnosis. However, the shortage of skilled and technically knowledgeable laboratory technicians to operate advanced molecular diagnostic products has hindered their overall adoption, particularly in emerging markets.

Molecular Diagnostics Ecosystem/Market Map

Molecular Diagnostics Market Ecosystem

Reagents & kits segment accounted for the largest share of the molecular diagnostics industry in 2022, by product & service

The molecular diagnostics market is categorized into reagents & kits, instruments, and services & software based on product & service. The reagents & kits segment emerged as the dominant force in the market in 2022. The recurring cost associated with the frequent requirement of reagents & kits is a significant factor contributing to the market's growth. Furthermore, technological advancements in molecular diagnostics continuously drive the development of new and improved reagents and kits. The availability of advanced reagents and kits that offer enhanced performance and reliability fosters their widespread adoption and contributes to the segment's growth.

Lab tests segment accounted for the largest share in the molecular diagnostics industry in 2022, by test type

The global molecular diagnostics market is categorized into lab tests and PoC tests based on test type. In 2022, the lab tests segment held the largest share in the market, categorized by test type. The growth of this segment can be attributed to factors such as the growing demand for automation in laboratory settings and the increasing incidence of various infectious diseases.

Lab tests generally have higher sensitivity and specificity compared to PoC tests. The controlled laboratory environment allows for more accurate and precise measurements, reducing the chances of false-negative or false-positive results. This is particularly crucial in infectious disease diagnostics where accuracy is paramount for appropriate treatment and containment measures. Another advantage of lab tests is the ability to process a large volume of samples simultaneously. Automated platforms and high-throughput systems in laboratories can handle a high sample throughput, enabling efficient testing for infectious diseases. Such factors are expected to fuel the growth of this segment.

Blood, serum, and plasma, urine, and other sample types segment accounted for the largest share in the molecular diagnostics industry in 2022, by sample type

Based on sample type, the molecular diagnostics market has been segmented into blood, serum, and plasma, urine, and other sample types. In 2022, the blood, serum, and plasma segment accounted for the largest share of the market. These sample types provide a rich and diverse pool of molecular diagnostic information. They contain circulating DNA, RNA, proteins, and other biomarkers that carry valuable insights into various diseases and conditions. This wealth of information enables healthcare professionals to make accurate diagnoses, monitor disease progression, and personalize treatment decisions.

North America accounted for the largest share of the molecular diagnostics industry in 2022

The molecular diagnostics market is segmented into five major regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2022, North America emerged as the leading contributor, claiming the largest portion of the market share in the molecular diagnostics industry. North America has been at the forefront of technological advancements in the field of molecular diagnostics. The region has a robust infrastructure for R&D, which has led to the rapid adoption of innovative diagnostic techniques and platforms. Also, North America houses several major companies operating in the molecular diagnostics sector. These companies have significant expertise, resources, and established distribution networks, which contribute to the region's market dominance. Examples of prominent molecular diagnostics companies in North America include Hologic, Inc. (US), PerkinElmer, Inc. (US), Abbott Laboratories (US), and Thermo Fisher Scientific Inc. (US).

Molecular Diagnostics Market by Region

To know about the assumptions considered for the study, download the pdf brochure

The major players in this market are Danaher (US), F. Hoffmann-La Roche Ltd. (Switzerland), Hologic, Inc. (US), Abbott Laboratories (US), Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), bioMérieux (France), and QIAGEN (Netherlands). The market leadership of these players stems from their comprehensive product portfolios and expansive global footprint. These dominant market players possess several advantages, including strong marketing and distribution networks, substantial research and development budgets, and well-established brand recognition.

Scope of the Molecular Diagnostics Industry:

Report Metric

Details

Market Revenue in 2023

$15.6 billion

Estimated Value by 2028

$26.8 billion

Revenue Rate

Poised to grow at a CAGR of 11.4%

Market Driver

Rising technological advancements in molecular diagnostics in recent years

Market Opportunity

Growing significance of companion diagnostics in drug development process

This report categorizes the molecular diagnostics market to forecast revenue and analyze trends in each of the following submarkets:

By Product & Service

  • Reagents & Kits
  • Instruments
  • Services & Software

By Test Type

  • Lab Tests
  • PoC Tests

By Sample Type

  • Blood, Serum, and Plasma
  • Urine
  • Other Sample Types

By Technology

  • Polymerase Chain Reaction
  • Isothermal Nucleic Acid Amplification Technology
  • DNA Sequencing & Next- generation Sequencing
  • In Situ Hybridization
  • DNA Microarrays
  • Other Technologies

By Application

  • Infectious Disease Diagnostics
    • Hepatitis
    • HIV
    • CT/NG
    • HAI
    • HPV
    • Tuberculosis
    • Influenza
    • Other Infectious Diseases
  • Oncology Testing
    • Breast Cancer
    • Colorectal Cancer
    • Lung Cancer
    • Prostate Cancer
    • Other Cancers
  • Genetic Testing
  • Other Applications
  • COVID-19

By End User

  • Diagnostic Laboratories
  • Hospitals & Clinics
  • Other End Users

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Russia
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa

Recent Developments of Molecular Diagnostics Industry

  • In February 2023, Thermo Fisher Scientific Inc. (US) acquired Binding Site Group (UK), a global leader in specialty diagnostics, to expand Thermo Fisher’s existing specialty diagnostics portfolio with the addition of pioneering innovation in diagnostics and monitoring for multiple myeloma.
  • In October 2022, F. Hoffmann-La Roche Ltd. (Switzerland) received 510(k) clearance from the US FDA for the cobas SARS-CoV-2 Qualitative PCR test for use on the fully automated cobas 6800 and cobas 8800 Systems.
  • In May 2022, F. Hoffmann-La Roche Ltd. (Switzerland) partnered with Global Fund to support low- and middle-income countries in strengthening critical diagnostics infrastructure.
  • In December 2021, Hologic, Inc. (US) launched Panther Trax for high-volume molecular testing.
  • In March 2021, Abbott Laboratories (US) received Emergency Use Authorization (EUA) from the FDA for a laboratory PCR assay, Alinity m Resp-4-Plex molecular assay, that detects and differentiates between SARS-COV-2, flu A, flu B, and RSV in one test.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 36)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 STUDY SCOPE 
           1.3.1 MOLECULAR DIAGNOSTICS MARKET: MARKET SEGMENTATION
           1.3.2 MOLECULAR DIAGNOSTICS INDUSTRY: GEOGRAPHICAL SEGMENTATION
           1.3.3 YEARS CONSIDERED
    1.4 CURRENCY CONSIDERED 
    1.5 MARKET LIMITATIONS 
    1.6 STAKEHOLDERS 
    1.7 SUMMARY OF CHANGES 
 
2 RESEARCH METHODOLOGY (Page No. - 42)
    2.1 RESEARCH DATA 
    2.2 RESEARCH APPROACH 
          FIGURE 1 MOLECULAR DIAGNOSTICS MARKET SIZE: RESEARCH DESIGN METHODOLOGY
           2.2.1 SECONDARY DATA
                    2.2.1.1 Key data from secondary sources
           2.2.2 PRIMARY DATA
                    2.2.2.1 Primary sources
                    2.2.2.2 Key data from primary sources
                    2.2.2.3 Key industry insights
                    2.2.2.4 Breakdown of primary interviews
                                FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE AND DEMAND SIDE PARTICIPANTS
                                FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
    2.3 MARKET SIZE ESTIMATION 
           2.3.1 BOTTOM-UP APPROACH
                    2.3.1.1 Approach 1: Company revenue estimation approach
                                FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
                    2.3.1.2 Approach 2: Company presentations and primary interviews
                    2.3.1.3 Growth forecast
                    2.3.1.4 CAGR projections
                                FIGURE 5 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS
           2.3.2 TOP-DOWN APPROACH
                    FIGURE 6 MOLECULAR DIAGNOSTICS INDUSTRY: TOP-DOWN APPROACH
    2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 
          FIGURE 7 DATA TRIANGULATION METHODOLOGY
    2.5 MARKET SHARE ANALYSIS 
    2.6 STUDY ASSUMPTIONS 
    2.7 RESEARCH LIMITATIONS 
    2.8 GROWTH RATE ASSUMPTIONS 
    2.9 RISK ASSESSMENT 
           2.9.1 RISK ASSESSMENT OF MARKET
    2.1 IMPACT OF ECONOMIC RECESSION ON MARKET 
 
3 EXECUTIVE SUMMARY (Page No. - 57)
    FIGURE 8 MOLECULAR DIAGNOSTICS MARKET GROWTH, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION)
    FIGURE 9 MOLECULAR DIAGNOSTICS INDUSTRY, BY TEST TYPE, 2023 VS. 2028 (USD MILLION)
    FIGURE 10 MARKET, BY SAMPLE TYPE, 2023 VS. 2028 (USD MILLION)
    FIGURE 11 MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)
    FIGURE 12 MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
    FIGURE 13 MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    FIGURE 14 MARKET, BY REGION, 2023 VS. 2028 (USD MILLION)
 
4 PREMIUM INSIGHTS (Page No. - 63)
    4.1 MOLECULAR DIAGNOSTICS MARKET GROWTH OVERVIEW 
          FIGURE 15 INCREASING PREVALENCE OF INFECTIOUS DISEASES AND RISING INCIDENCE OF CANCER TO SUPPORT MARKET
    4.2 MOLECULAR DIAGNOSTICS INDUSTRY, BY PRODUCT & SERVICE, 2023 VS. 2028 
          FIGURE 16 REAGENTS & KITS TO DOMINATE MARKET IN 2028
    4.3 MARKET, BY TEST TYPE, 2023 VS. 2028 
          FIGURE 17 LAB TESTS TO COMMAND GREATER MARKET SHARE IN 2028
    4.4 MARKET, BY SAMPLE TYPE, 2023 VS. 2028 
          FIGURE 18 BLOOD, SERUM, AND PLASMA SEGMENT TO DOMINATE MARKET DURING STUDY PERIOD
    4.5 MOLECULAR DIAGNOSTICS MARKET REPORT, BY TECHNOLOGY, 2023 VS. 2028 
          FIGURE 19 PCR SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
    4.6 MARKET, BY APPLICATION, 2023 VS. 2028 
          FIGURE 20 INFECTIOUS DISEASE DIAGNOSTICS SEGMENT TO DOMINATE MARKET IN 2028
    4.7 MARKET, BY END USER, 2023 VS. 2028 
          FIGURE 21 DIAGNOSTIC LABORATORIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
    4.8 MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES 
          FIGURE 22 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN MARKET DURING STUDY PERIOD
 
5 MARKET OVERVIEW (Page No. - 67)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 23 MOLECULAR DIAGNOSTICS MARKET GROWTH: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Increasing prevalence of infectious diseases and cancer globally
                                TABLE 1 ESTIMATED NUMBER OF NEW CANCER CASES GLOBALLY, BY TYPE OF CANCER, 2020 VS. 2025
                                TABLE 2 GLOBAL CANCER INCIDENCE, BY REGION, 2020 VS. 2025
                    5.2.1.2 Rising focus on R&D and growing funding in molecular diagnostics by healthcare-based companies
                    5.2.1.3 Growing awareness regarding early disease diagnosis in developing countries
                    5.2.1.4 Rising technological advancements in molecular diagnostics in recent years
                    5.2.1.5 Increasing use of PoC diagnostic tests in homecare settings and hospitals
           5.2.2 RESTRAINTS
                    5.2.2.1 Unfavorable reimbursement scenario for diagnostic companies
                    5.2.2.2 High cost of molecular diagnostic instruments
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Growing significance of companion diagnostics in drug development process
                    5.2.3.2 Increasing growth opportunities for molecular diagnostics companies in emerging economies
           5.2.4 CHALLENGES
                    5.2.4.1 Changing regulatory landscape for IVD and molecular diagnostics in US and European Union
                    5.2.4.2 Operational barriers and shortage of skills across major markets
                    5.2.4.3 Introduction of alternative technologies for disease detection and diagnosis
    5.3 PRICING ANALYSIS 
           5.3.1 AVERAGE SELLING PRICE OF MOLECULAR DIAGNOSTICS PRODUCTS, BY KEY PLAYER
                    TABLE 3 AVERAGE SELLING PRICE OF MOLECULAR DIAGNOSTIC PRODUCTS
    5.4 PATENT ANALYSIS 
          FIGURE 24 PATENT ANALYSIS FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGIES (JANUARY 2013–DECEMBER 2022)
           5.4.1 LIST OF MAJOR PATENTS
    5.5 VALUE CHAIN ANALYSIS 
          FIGURE 25 VALUE CHAIN ANALYSIS OF MOLECULAR DIAGNOSTICS INDUSTRY: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
    5.6 SUPPLY CHAIN ANALYSIS 
          FIGURE 26 MARKET: SUPPLY CHAIN ANALYSIS
    5.7 ECOSYSTEM/MARKET MAP ANALYSIS 
          FIGURE 27 MARKET: ECOSYSTEM/MARKET MAP ANALYSIS
           5.7.1 MOLECULAR DIAGNOSTICS MARKET REPORT: ROLE IN ECOSYSTEM
    5.8 PORTER’S FIVE FORCES ANALYSIS 
          TABLE 4 MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.8.1 THREAT FROM NEW ENTRANTS
           5.8.2 THREAT FROM SUBSTITUTES
           5.8.3 BARGAINING POWER OF BUYERS
           5.8.4 BARGAINING POWER OF SUPPLIERS
           5.8.5 INTENSITY OF COMPETITIVE RIVALRY
    5.9 REGULATORY ANALYSIS 
          TABLE 5 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
          TABLE 6 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
          TABLE 7 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
          TABLE 8 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
           5.9.1 NORTH AMERICA
                    5.9.1.1 US
                    5.9.1.2 Canada
           5.9.2 EUROPE
                    TABLE 9 EUROPE: CLASSIFICATION OF DEVICES
           5.9.3 ASIA PACIFIC
                    5.9.3.1 China
                    5.9.3.2 Japan
                                TABLE 10 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
                    5.9.3.3 India
           5.9.4 LATIN AMERICA
                    5.9.4.1 Brazil
                    5.9.4.2 Mexico
           5.9.5 MIDDLE EAST
           5.9.6 AFRICA
    5.10 TRADE ANALYSIS 
           5.10.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
                    5.10.1.1 Import data for diagnostic and laboratory reagents, by country, 2018–2022 (USD million)
                    5.10.1.2 Export data for diagnostic and laboratory reagents, by country, 2018–2022 (USD million)
    5.11 TECHNOLOGY ANALYSIS 
    5.12 KEY CONFERENCES AND EVENTS IN 2023–2024 
           TABLE 11 MARKET: DETAILED LIST OF CONFERENCES AND EVENTS IN 2023–2024
    5.13 PESTLE ANALYSIS 
    5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 
           5.14.1 REVENUE SHIFT IN MARKET
    5.15 KEY STAKEHOLDERS AND BUYING CRITERIA 
           5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
                     FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF MOLECULAR DIAGNOSTIC PRODUCTS
                     TABLE 12 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF MOLECULAR DIAGNOSTIC PRODUCTS (%)
           5.15.2 BUYING CRITERIA
                     FIGURE 29 KEY BUYING CRITERIA FOR MOLECULAR DIAGNOSTIC PRODUCTS
                     TABLE 13 KEY BUYING CRITERIA FOR MOLECULAR DIAGNOSTIC PRODUCTS
    5.16 CASE STUDY ANALYSIS 
           FIGURE 30 CASE STUDY: MARKET ASSESSMENT AND CONSUMER BUYING BEHAVIOR IN INDIA
 
6 MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE (Page No. - 98)
    6.1 INTRODUCTION 
          TABLE 14 MOLECULAR DIAGNOSTICS INDUSTRY, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
          TABLE 15 PRICE OF MOLECULAR DIAGNOSTIC PRODUCTS (2022)
    6.2 REAGENTS & KITS 
           6.2.1 RECURRENT PURCHASES OF REAGENTS & KITS FOR DIAGNOSTIC ANALYSIS TO PROPEL MARKET
                    TABLE 16 MOLECULAR DIAGNOSTICS MARKET REPORT FOR REAGENTS & KITS, BY REGION, 2021–2028 (USD MILLION)
    6.3 INSTRUMENTS 
           6.3.1 INCREASING NEED FOR FASTER AND MORE ACCURATE TEST RESULTS TO BOOST MARKET
                    TABLE 17 KEY INSTRUMENTS AVAILABLE IN GLOBAL MARKET
                    TABLE 18 MARKET FOR INSTRUMENTS, BY REGION, 2021–2028 (USD MILLION)
    6.4 SERVICES & SOFTWARE 
           6.4.1 INCREASING UPTAKE OF ADVANCED INSTRUMENTS IN MARKET TO DRIVE GROWTH
                    TABLE 19 MARKET FOR SERVICES & SOFTWARE, BY REGION, 2021–2028 (USD MILLION)
 
7 MOLECULAR DIAGNOSTICS MARKET FORECAST, BY TEST TYPE (Page No. - 105)
    7.1 INTRODUCTION 
          TABLE 20 MOLECULAR DIAGNOSTICS INDUSTRY, BY TEST TYPE, 2021–2028 (USD MILLION)
           7.1.1 PRIMARY NOTES
                    7.1.1.1 Key industry insights
    7.2 LAB TESTS 
           7.2.1 ADVANCEMENTS IN DIAGNOSTIC TECHNOLOGIES AND INCREASED FOCUS ON EARLY DISEASE DETECTION TO DRIVE MARKET
                    TABLE 21 MOLECULAR DIAGNOSTICS MARKET REPORT FOR LAB TESTS, BY REGION, 2021–2028 (USD MILLION)
    7.3 POC TESTS 
           7.3.1 FASTER TURNAROUND TIME OF POC TESTS TO DRIVE SEGMENT GROWTH
                    TABLE 22 MARKET FOR POC TESTS, BY REGION, 2021–2028 (USD MILLION)
 
8 MOLECULAR DIAGNOSTICS MARKET FORECAST, BY SAMPLE TYPE (Page No. - 110)
    8.1 INTRODUCTION 
          TABLE 23 MOLECULAR DIAGNOSTICS INDUSTRY, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
    8.2 BLOOD, SERUM, AND PLASMA 
           8.2.1 UTILIZATION OF BLOOD SAMPLES IN DETECTING AND MANAGING INFECTIOUS DISEASES TO DRIVE MARKET
                    TABLE 24 MARKET FOR BLOOD, SERUM, AND PLASMA, BY REGION, 2021–2028 (USD MILLION)
    8.3 URINE 
           8.3.1 NON-INVASIVE NATURE OF URINE SAMPLES TO FUEL SEGMENT GROWTH
                    TABLE 25 MARKET FOR URINE, BY REGION, 2021–2028 (USD MILLION)
    8.4 OTHER SAMPLE TYPES 
          TABLE 26 MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2021–2028 (USD MILLION)
 
9 MOLECULAR DIAGNOSTICS MARKET FORECAST, BY TECHNOLOGY (Page No. - 114)
    9.1 INTRODUCTION 
           9.1.1 PRIMARY NOTES
                    9.1.1.1 Key industry insights
                                TABLE 27 MOLECULAR DIAGNOSTICS INDUSTRY, BY TECHNOLOGY, 2021–2028 (USD MILLION)
    9.2 POLYMERASE CHAIN REACTION 
           9.2.1 GROWING USE OF POLYMERASE CHAIN REACTION IN PROTEOMICS AND GENOMICS TO DRIVE MARKET
                    TABLE 28 MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2021–2028 (USD MILLION)
    9.3 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY 
           9.3.1 COST BENEFITS OF ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY IN NUCLEIC ACID SEQUENCING TO DRIVE MARKET
                    TABLE 29 MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2021–2028 (USD MILLION)
    9.4 DNA SEQUENCING & NEXT-GENERATION SEQUENCING 
           9.4.1 INCREASING USE OF NEXT-GENERATION SEQUENCING IN CANCER DIAGNOSIS TO FUEL MARKET
                    TABLE 30 MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2021–2028 (USD MILLION)
    9.5 IN SITU HYBRIDIZATION 
           9.5.1 RISING PREVALENCE OF CANCER AND GENETIC DISORDERS TO DRIVE MARKET
                    TABLE 31 MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2021–2028 (USD MILLION)
    9.6 DNA MICROARRAYS 
           9.6.1 INTRODUCTION OF DNA MICROARRAYS TO ACCELERATE GENE EXPRESSION AND DISEASE DIAGNOSIS
                    TABLE 32 MARKET FOR DNA MICROARRAYS, BY REGION, 2021–2028 (USD MILLION)
    9.7 OTHER TECHNOLOGIES 
          TABLE 33 MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021–2028 (USD MILLION)
 
10 MOLECULAR DIAGNOSTICS MARKET FORECAST, BY APPLICATION (Page No. - 124)
     10.1 INTRODUCTION 
             TABLE 34 MOLECULAR DIAGNOSTICS INDUSTRY, BY APPLICATION, 2021–2028 (USD MILLION)
     10.2 INFECTIOUS DISEASE DIAGNOSTICS 
             TABLE 35 MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY REGION, 2021–2028 (USD MILLION)
             TABLE 36 MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
             10.2.1 HEPATITIS
                        10.2.1.1 Increasing adoption of advanced technologies for diagnosis of hepatitis B to drive segment
                                      TABLE 37 HEPATITIS MARKET, BY REGION, 2021–2028 (USD MILLION)
                                      TABLE 38 HEPATITIS MARKET, BY REGION, 2021–2028 (MILLION TESTS)
             10.2.2 HIV
                        10.2.2.1 Increased global prevalence of HIV to propel segment
                                      TABLE 39 HIV MARKET, BY REGION, 2021–2028 (USD MILLION)
                                      TABLE 40 HIV MARKET, BY REGION, 2021–2028 (MILLION TESTS)
             10.2.3 CT/NG
                        10.2.3.1 CT/NG infections to be most common sexually transmitted disease globally
                                      TABLE 41 CT/NG MARKET, BY REGION, 2021–2028 (USD MILLION)
                                      TABLE 42 CT/NG MARKET, BY REGION, 2021–2028 (MILLION TESTS)
             10.2.4 HAIS
                        10.2.4.1 Rising burden of MRSA infections and increasing adoption of technologically advanced HAI diagnostic tests to aid market
                                      TABLE 43 HAIS MARKET, BY REGION, 2021–2028 (USD MILLION)
                                      TABLE 44 HAIS MARKET, BY REGION, 2021–2028 (MILLION TESTS)
             10.2.5 HPV
                        10.2.5.1 Technological advancements for preventing HPV infections to augment market
                                      TABLE 45 HPV MARKET, BY REGION, 2021–2028 (USD MILLION)
                                      TABLE 46 HPV MARKET, BY REGION, 2021–2028 (MILLION TESTS)
             10.2.6 TUBERCULOSIS
                        10.2.6.1 Increasing burden of tuberculosis globally to propel market
                                      TABLE 47 TUBERCULOSIS MARKET, BY REGION, 2021–2028 (USD MILLION)
                                      TABLE 48 TUBERCULOSIS MARKET, BY REGION, 2021–2028 (MILLION TESTS)
             10.2.7 INFLUENZA
                        10.2.7.1 Rising focus on decreasing spread of influenza to propel segment
                                      TABLE 49 INFLUENZA MARKET, BY REGION, 2021–2028 (USD MILLION)
                                      TABLE 50 INFLUENZA MARKET, BY REGION, 2021–2028 (MILLION TESTS)
             10.2.8 OTHER INFECTIOUS DISEASES
                       TABLE 51 OTHER INFECTIOUS DISEASES MARKET, BY REGION, 2021–2028 (USD MILLION)
     10.3 ONCOLOGY TESTING 
            TABLE 52 MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
            TABLE 53 MARKET FOR ONCOLOGY TESTING, BY REGION, 2021–2028 (USD MILLION)
             10.3.1 BREAST CANCER
                        10.3.1.1 Increasing prevalence of breast cancer among females to boost market
                                      TABLE 54 BREAST CANCER INCIDENCE, BY REGION, 2020 VS. 2040
                                      TABLE 55 BREAST CANCER MARKET, BY REGION, 2021–2028 (USD MILLION)
             10.3.2 COLORECTAL CANCER
                        10.3.2.1 Rising focus on development of companion diagnostic assays to fuel market
                                      TABLE 56 COLORECTAL CANCER MARKET, BY REGION, 2021–2028 (USD MILLION)
             10.3.3 LUNG CANCER
                        10.3.3.1 Increasing research for lung cancer biomarkers to drive market
                                      TABLE 57 LUNG CANCER MARKET, BY REGION, 2021–2028 (USD MILLION)
             10.3.4 PROSTATE CANCER
                        10.3.4.1 Advancements in genomic technologies for development of new biomarkers to aid market
                                      TABLE 58 PROSTATE CANCER MARKET, BY REGION, 2021–2028 (USD MILLION)
             10.3.5 OTHER CANCERS
                        TABLE 59 GLOBAL CANCER INCIDENCE, 2020
                        TABLE 60 OTHER CANCERS MARKET, BY REGION, 2021–2028 (USD MILLION)
     10.4 GENETIC TESTING 
             10.4.1 DIAGNOSIS OF VARIOUS DISEASES THROUGH GENETIC TESTING METHODS TO PROPEL MARKET
                        TABLE 61 MARKET FOR GENETIC TESTING, BY REGION, 2021–2028 (USD MILLION)
     10.5 OTHER APPLICATIONS 
             TABLE 62 MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
     10.6 COVID-19 
             10.6.1 DECLINING CASES OF COVID-19 TO HINDER MARKET
                        TABLE 63 MARKET FOR COVID-19, BY REGION, 2021–2028 (USD MILLION)
 
11 MOLECULAR DIAGNOSTICS MARKET FORECAST, BY END USER (Page No. - 146)
     11.1 INTRODUCTION 
             TABLE 64 MOLECULAR DIAGNOSTICS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
     11.2 DIAGNOSTIC LABORATORIES 
             11.2.1 INCREASED OUTSOURCING OF LABORATORY DIAGNOSES FOR REDUCTION IN COSTS TO DRIVE MARKET
                        TABLE 65 MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2021–2028 (USD MILLION)
     11.3 HOSPITALS & CLINICS 
             11.3.1 GREATER NUMBER OF HOSPITALS AND HIGHER GOVERNMENT INVESTMENTS IN HEALTHCARE TO BOOST SEGMENT
                        TABLE 66 MOLECULAR DIAGNOSTICS MARKET REPORT FOR HOSPITALS & CLINICS, BY REGION, 2021–2028 (USD MILLION)
     11.4 OTHER END USERS 
             TABLE 67 MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION)
 
12 MOLECULAR DIAGNOSTICS MARKET GROWTH, BY REGION (Page No. - 151)
     12.1 INTRODUCTION 
             TABLE 68 MOLECULAR DIAGNOSTICS INDUSTRY, BY REGION, 2021–2028 (USD MILLION)
     12.2 NORTH AMERICA 
             FIGURE 31 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET SNAPSHOT
             TABLE 69 NORTH AMERICA: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 70 NORTH AMERICA: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
             TABLE 71 NORTH AMERICA: MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
             TABLE 72 NORTH AMERICA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
             TABLE 73 NORTH AMERICA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 74 NORTH AMERICA: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 75 NORTH AMERICA: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 76 NORTH AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.2.1 IMPACT OF ECONOMIC RECESSION ON NORTH AMERICA
             12.2.2 US
                        12.2.2.1 Increasing prevalence of infectious diseases and cancer to drive market
                                      TABLE 77 US: MOLECULAR DIAGNOSTICS MARKET ANALYSIS, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 78 US: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 79 US: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 80 US: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 81 US: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 82 US: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.2.3 CANADA
                        12.2.3.1 High availability of funding for genomics research to fuel market
                                      TABLE 83 CANADA: MOLECULAR DIAGNOSTICS MARKET PREDICTION, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 84 CANADA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 85 CANADA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 86 CANADA: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 87 CANADA: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 88 CANADA: MARKET, BY END USER, 2021–2028 (USD MILLION)
     12.3 EUROPE 
             TABLE 89 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 90 EUROPE: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
             TABLE 91 EUROPE: MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
             TABLE 92 EUROPE: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
             TABLE 93 EUROPE: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 94 EUROPE: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 95 EUROPE: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 96 EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.3.1 IMPACT OF ECONOMIC RECESSION ON EUROPE
             12.3.2 GERMANY
                        12.3.2.1 Increasing healthcare expenditure with favorable government policies and rising per capita disposable income to propel market
                                      TABLE 97 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 98 GERMANY: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 99 GERMANY: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 100 GERMANY: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 101 GERMANY: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 102 GERMANY: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.3.3 UK
                        12.3.3.1 Growing number of accredited diagnostic laboratories to fuel market
                                      TABLE 103 UK: MOLECULAR DIAGNOSTICS MARKET ANALYSIS, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 104 UK: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 105 UK: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 106 UK: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 107 UK: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 108 UK: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.3.4 FRANCE
                        12.3.4.1 Rising R&D expenditure and increasing demand for early disease diagnosis to augment market
                                      TABLE 109 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 110 FRANCE: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 111 FRANCE: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 112 FRANCE: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 113 FRANCE: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 114 FRANCE: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.3.5 ITALY
                        12.3.5.1 Adoption of advanced diagnostic technologies to support market
                                      TABLE 115 ITALY: MOLECULAR DIAGNOSTICS MARKET PREDICTION, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 116 ITALY: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 117 ITALY: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 118 ITALY: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 119 ITALY: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 120 ITALY: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.3.6 SPAIN
                        12.3.6.1 Growing demand for genetic testing to create major growth opportunities for market players
                                      TABLE 121 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 122 SPAIN: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 123 SPAIN: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 124 SPAIN: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 125 SPAIN: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 126 SPAIN: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.3.7 RUSSIA
                        12.3.7.1 Increasing access to quality healthcare and growing incidence of infectious diseases to aid market
                                      TABLE 127 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 128 RUSSIA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 129 RUSSIA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 130 RUSSIA: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 131 RUSSIA: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 132 RUSSIA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.3.8 REST OF EUROPE
                        TABLE 133 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET ANALYSIS, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                        TABLE 134 REST OF EUROPE: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 135 REST OF EUROPE: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 136 REST OF EUROPE: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 137 REST OF EUROPE: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 138 REST OF EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
     12.4 ASIA PACIFIC 
             FIGURE 32 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET SNAPSHOT
             TABLE 139 ASIA PACIFIC: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 140 ASIA PACIFIC: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
             TABLE 141 ASIA PACIFIC: MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
             TABLE 142 ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
             TABLE 143 ASIA PACIFIC: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 144 ASIA PACIFIC: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 145 ASIA PACIFIC: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 146 ASIA PACIFIC: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.4.1 IMPACT OF ECONOMIC RECESSION ON ASIA PACIFIC
             12.4.2 CHINA
                        12.4.2.1 Rapid economic growth and greater public access to modern healthcare to drive market
                                      TABLE 147 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 148 CHINA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 149 CHINA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 150 CHINA: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 151 CHINA: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 152 CHINA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.4.3 JAPAN
                        12.4.3.1 Universal healthcare reimbursement policy to support market
                                      TABLE 153 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 154 JAPAN: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 155 JAPAN: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 156 JAPAN: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 157 JAPAN: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 158 JAPAN: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.4.4 INDIA
                        12.4.4.1 Increased private & public investments and large patient population to drive market
                                      TABLE 159 INDIA: MOLECULAR DIAGNOSTICS MARKET ANALYSIS, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 160 INDIA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 161 INDIA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 162 INDIA: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 163 INDIA: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 164 INDIA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.4.5 AUSTRALIA
                        12.4.5.1 High prevalence of infectious diseases to fuel market
                                      TABLE 165 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET PREDICTION, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 166 AUSTRALIA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 167 AUSTRALIA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 168 AUSTRALIA: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 169 AUSTRALIA: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 170 AUSTRALIA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.4.6 REST OF ASIA PACIFIC
                        TABLE 171 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                        TABLE 172 REST OF ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 173 REST OF ASIA PACIFIC: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 174 REST OF ASIA PACIFIC: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 175 REST OF ASIA PACIFIC: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 176 REST OF ASIA PACIFIC: MARKET, BY END USER, 2021–2028 (USD MILLION)
     12.5 LATIN AMERICA 
             TABLE 177 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 178 LATIN AMERICA: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
             TABLE 179 LATIN AMERICA: MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
             TABLE 180 LATIN AMERICA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
             TABLE 181 LATIN AMERICA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 182 LATIN AMERICA: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 183 LATIN AMERICA: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 184 LATIN AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.5.1 IMPACT OF ECONOMIC RECESSION ON LATIN AMERICA
             12.5.2 BRAZIL
                        12.5.2.1 Improving healthcare infrastructure and stringent regulations to fuel market
                                      TABLE 185 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 186 BRAZIL: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 187 BRAZIL: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 188 BRAZIL: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 189 BRAZIL: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 190 BRAZIL: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.5.3 MEXICO
                        12.5.3.1 Improving accessibility and affordability of healthcare services to aid market
                                      TABLE 191 MEXICO: MOLECULAR DIAGNOSTICS MARKET ANALYSIS, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 192 MEXICO: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 193 MEXICO: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 194 MEXICO: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 195 MEXICO: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 196 MEXICO: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.5.4 REST OF LATIN AMERICA
                        TABLE 197 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                        TABLE 198 REST OF LATIN AMERICA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 199 REST OF LATIN AMERICA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 200 REST OF LATIN AMERICA: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 201 REST OF LATIN AMERICA: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 202 REST OF LATIN AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
     12.6 MIDDLE EAST & AFRICA 
             12.6.1 ADVANCEMENTS IN DIAGNOSTIC TECHNOLOGIES AND INCREASED HEALTHCARE INVESTMENTS TO PROPEL MARKET
                        TABLE 203 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET PREDICTION, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                        TABLE 204 MIDDLE EAST & AFRICA: MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
                        TABLE 205 MIDDLE EAST & AFRICA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 206 MIDDLE EAST & AFRICA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 207 MIDDLE EAST & AFRICA: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 208 MIDDLE EAST & AFRICA: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 209 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.6.2 IMPACT OF ECONOMIC RECESSION ON MIDDLE EAST & AFRICA
 
13 COMPETITIVE LANDSCAPE (Page No. - 229)
     13.1 OVERVIEW 
     13.2 STRATEGIES ADOPTED BY KEY PLAYERS 
             13.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN MOLECULAR DIAGNOSTICS MARKET
                        TABLE 210 OVERVIEW OF STRATEGIES DEPLOYED BY KEY MOLECULAR DIAGNOSTIC MANUFACTURING COMPANIES
     13.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 
             FIGURE 33 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN MOLECULAR DIAGNOSTICS INDUSTRY
     13.4 MARKET SHARE ANALYSIS 
             FIGURE 34 MOLECULAR DIAGNOSTICS INDUSTRY SHARE, BY KEY PLAYER (2022)
             TABLE 211 MOLECULAR DIAGNOSTICS INDUSTRY: DEGREE OF COMPETITION
             13.4.1 MOLECULAR DIAGNOSTICS INDUSTRY SHARE AND RANKING ANALYSIS, BY TECHNOLOGY
                        13.4.1.1 Polymerase chain reaction (PCR)
                                      TABLE 212 GLOBAL MOLECULAR DIAGNOSTICS INDUSTRY RANKING FOR PCR, BY KEY PLAYER, 2022
                        13.4.1.2 DNA sequencing and NGS
                                      TABLE 213 GLOBAL MOLECULAR DIAGNOSTICS INDUSTRY RANKING FOR DNA SEQUENCING AND NGS, BY KEY PLAYER, 2022
                        13.4.1.3 Isothermal nucleic acid amplification technology (INAAT)
                                      TABLE 214 GLOBAL MOLECULAR DIAGNOSTICS INDUSTRY RANKING FOR INAAT, BY KEY PLAYER, 2022
                        13.4.1.4 In situ hybridization (ISH)
                                      TABLE 215 GLOBAL MOLECULAR DIAGNOSTICS INDUSTRY RANKING FOR ISH, BY KEY PLAYER, 2022
             13.4.2 MOLECULAR DIAGNOSTICS MARKET GROWTH - RANKING ANALYSIS, BY APPLICATION
                        13.4.2.1 Infectious diseases
                                      TABLE 216 GLOBAL MOLECULAR DIAGNOSTICS INDUSTRY RANKING FOR INFECTIOUS DISEASES, BY KEY PLAYER, 2022
     13.5 COMPANY EVALUATION MATRIX FOR KEY PLAYERS 
             13.5.1 LIST OF EVALUATED VENDORS
             13.5.2 STARS
             13.5.3 EMERGING LEADERS
             13.5.4 PERVASIVE PLAYERS
             13.5.5 PARTICIPANTS
                        FIGURE 35 MOLECULAR DIAGNOSTICS INDUSTRY: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022
     13.6 COMPANY EVALUATION MATRIX FOR START-UPS/SMES (2022) 
             13.6.1 PROGRESSIVE COMPANIES
             13.6.2 STARTING BLOCKS
             13.6.3 RESPONSIVE COMPANIES
             13.6.4 DYNAMIC COMPANIES
                        FIGURE 36 MOLECULAR DIAGNOSTICS INDUSTRY: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022
     13.7 COMPETITIVE BENCHMARKING 
             13.7.1 PRODUCT AND GEOGRAPHICAL FOOTPRINT ANALYSIS
                        FIGURE 37 PRODUCT AND GEOGRAPHICAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN MOLECULAR DIAGNOSTICS INDUSTRY
                        TABLE 217 MOLECULAR DIAGNOSTICS INDUSTRY: COMPETITIVE BENCHMARKING OF KEY PLAYERS
                        TABLE 218 COMPANY PRODUCT & SERVICE FOOTPRINT
                        TABLE 219 COMPANY REGIONAL FOOTPRINT
                        TABLE 220 MOLECULAR DIAGNOSTICS MARKET PREDICTION: DETAILED LIST OF KEY START-UPS/SMES
     13.8 COMPETITIVE SCENARIO 
             13.8.1 KEY PRODUCT LAUNCHES
                        TABLE 221 KEY PRODUCT LAUNCHES AND REGULATORY APPROVALS
             13.8.2 KEY DEALS
                        TABLE 222 KEY DEALS
 
14 COMPANY PROFILES (Page No. - 245)
     14.1 KEY PLAYERS 
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
             14.1.1 DANAHER
                        TABLE 223 DANAHER: COMPANY OVERVIEW
                        FIGURE 38 DANAHER: COMPANY SNAPSHOT (2022)
             14.1.2 F. HOFFMANN-LA ROCHE LTD.
                        TABLE 224 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
                        FIGURE 39 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
             14.1.3 HOLOGIC, INC.
                        TABLE 225 HOLOGIC, INC.: COMPANY OVERVIEW
                        FIGURE 40 HOLOGIC, INC.: COMPANY SNAPSHOT (2022)
             14.1.4 ILLUMINA, INC.
                        TABLE 226 ILLUMINA, INC.: COMPANY OVERVIEW
                        FIGURE 41 ILLUMINA, INC.: COMPANY SNAPSHOT (2022)
             14.1.5 ABBOTT LABORATORIES
                        TABLE 227 ABBOTT LABORATORIES: COMPANY OVERVIEW
                        FIGURE 42 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022)
             14.1.6 BIOMÉRIEUX
                        TABLE 228 BIOMÉRIEUX: COMPANY OVERVIEW
                        FIGURE 43 BIOMÉRIEUX: COMPANY SNAPSHOT (2022)
             14.1.7 THERMO FISHER SCIENTIFIC INC.
                        TABLE 229 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
                        FIGURE 44 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
             14.1.8 QIAGEN
                        TABLE 230 QIAGEN: COMPANY OVERVIEW
                        FIGURE 45 QIAGEN: COMPANY SNAPSHOT (2022)
             14.1.9 REVVITY
                        TABLE 231 REVVITY: COMPANY OVERVIEW
                        FIGURE 46 REVVITY: COMPANY SNAPSHOT (2022)
             14.1.10 MYRIAD GENETICS, INC.
                        TABLE 232 MYRIAD GENETICS, INC.: COMPANY OVERVIEW
                        FIGURE 47 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2022)
             14.1.11 SIEMENS HEALTHINEERS AG
                        TABLE 233 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
                        FIGURE 48 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022)
     14.2 OTHER PLAYERS 
             14.2.1 BECTON, DICKINSON AND COMPANY
             14.2.2 GRIFOLS, S.A.
             14.2.3 QUIDELORTHO CORPORATION
             14.2.4 AGILENT TECHNOLOGIES, INC.
             14.2.5 DIASORIN S.P.A.
             14.2.6 EXACT SCIENCES CORPORATION
             14.2.7 GENETIC SIGNATURES
             14.2.8 MDXHEALTH
             14.2.9 HTG MOLECULAR DIAGNOSTICS, INC.
             14.2.10 BIOCARTIS
             14.2.11 TBG DIAGNOSTICS LIMITED
                        TABLE 234 TBG DIAGNOSTICS LIMITED: COMPANY OVERVIEW
             14.2.12 VELA DIAGNOSTICS
                        TABLE 235 VELA DIAGNOSTICS: COMPANY OVERVIEW
             14.2.13 AMOY DIAGNOSTICS CO., LTD.
                        TABLE 236 AMOY DIAGNOSTICS CO., LTD.: COMPANY OVERVIEW
             14.2.14 ELITECHGROUP
                        TABLE 237 ELITECHGROUP: COMPANY OVERVIEW
             14.2.15 MOLBIO DIAGNOSTICS PVT. LTD.
                        TABLE 238 MOLBIO DIAGNOSTICS PVT. LTD.: COMPANY OVERVIEW
             14.2.16 SAVYON DIAGNOSTICS
                        TABLE 239 SAVYON DIAGNOSTICS: COMPANY OVERVIEW
             14.2.17 ABACUS DIAGNOSTICA OY
                        TABLE 240 ABACUS DIAGNOSTICA OY.: COMPANY OVERVIEW
             14.2.18 GENEOMBIO TECHNOLOGIES PVT. LTD.
                        TABLE 241 GENEOMBIO TECHNOLOGIES PVT. LTD.: COMPANY OVERVIEW
 
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
 
15 APPENDIX (Page No. - 317)
     15.1 DISCUSSION GUIDE 
     15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     15.3 CUSTOMIZATION OPTIONS 
     15.4 RELATED REPORTS 
     15.5 AUTHOR DETAILS 

The objective of the study is analyze the key market dynamics such as drivers, opportunities, challenges, restraints, and key player strategies. To track companies developments such as acquisitions, product launches, expansions, agreements and partnerships of the leading players, the competitive landscape of the molecular diagnostics market to analyzes market players on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches were use to estimate the market size. To estimate the market size of segments and subsegments the market breakdown and data triangulation were used.

The four steps involved in estimating the market size are

Secondary Research

In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative and quantitative information as well as assess prospects.

The following is a breakdown of the primary respondents:

Breakdown of Primary Participants

Molecular Diagnostics Market Size, and Share

Note 1: Others include sales managers, marketing managers, and product managers.

Note 2: Companies are classified into tiers based on their total revenues. As of 2022, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = <USD 10 million.

To know about the assumptions considered for the study, download the pdf brochure

COMPANY NAME

DESIGNATION

Abbott

Marketing Manager

F. Hoffmann-La Roche Ltd

Senior Product Manager

Danaher

Marketing Manager

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the molecular diagnostics market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry have been identified through extensive secondary research
  • The revenues generated by leading players operating in the molecular diagnostics market have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Global Molecular Diagnostics Market Size: Botton Up Approach

Molecular Diagnostics Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Global Molecular Diagnostics market Size: Top-Down Approach

Molecular Diagnostics Market Size, and Share

Data Triangulation

After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Molecular diagnostics is a technique that identifies and analyzes nucleic acids or proteins at a molecular level. This technique assesses the genetic makeup of an individual to identify a predisposition to any particular disease or condition and diagnose it.

Key Stakeholders

  • Senior Management
  • End User
  • Finance/Procurement Department
  • R&D Department

Report Objectives

  • To define, describe, segment, and forecast the global molecular diagnostics market, by product & service, test type, sample type, technology, application, end user, and region
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall molecular diagnostics market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments with respect to five regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies2
  • To track and analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, and other developments
  • To benchmark players within the market using the proprietary Competitive Leadership Mapping framework, which analyzes market players on various parameters within the broad categories of business and product excellence

Available Customizations

MarketsandMarkets offers the following customizations for this market report

Country Information

  • Additional country-level analysis of the molecular diagnostics market

Company profiles

  • Additional five company profiles of players operating in the molecular diagnostics market.

Product Analysis

  • Product matrix, which provides a detailed comparison of the product portfolio of each company in the molecular diagnostics market
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
MD 2521
Published ON
Jun, 2023
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Molecular Diagnostics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback